AR019842A1 - DERIVATIVES OF NAFTO [2,3-B] HETEROAR-4-ILO, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A COMPOSITION THAT INCLUDES THEM. - Google Patents

DERIVATIVES OF NAFTO [2,3-B] HETEROAR-4-ILO, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A COMPOSITION THAT INCLUDES THEM.

Info

Publication number
AR019842A1
AR019842A1 ARP990102225A ARP990102225A AR019842A1 AR 019842 A1 AR019842 A1 AR 019842A1 AR P990102225 A ARP990102225 A AR P990102225A AR P990102225 A ARP990102225 A AR P990102225A AR 019842 A1 AR019842 A1 AR 019842A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
halogen
perfluoroalkyl
nitrile
Prior art date
Application number
ARP990102225A
Other languages
Spanish (es)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of AR019842A1 publication Critical patent/AR019842A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados de nafto [2,3-B] heteroar-4-ilo de formula 1, en donde R1 y R2 son cada uno, independientemetne, hidrogeno, nitrilo, nitro, amino, alquilaminoC1-6, dialquilamino C1-6 por grupo alquilo, cicloalquilamino C3-8, alquilo C1-6 perfluoralquilo C1-6, halogeno, cicloalquilo C3-8, tienilo, furilo, fenilo ofenilo mono-, di-, o trisustituido con halogeno, hidroxi, alquilo C1-6, perfluoroalquilo C1-6, alcoxi C1-6, o perfluoralcoxi C1-6; R3 y R4 son cada uno,independientemente, hidrogeno, alquilo C1-6, perfluoroalquilo C1-6, hidroxialquilo C1-6, aminoalquilo C1-6, acilo C2-7; R5 es hidrogeno, halogeno, alquiloC1-6, nitrilo, alcoxi C1-6, ariloxi, arilalcoxi C6-12, arilsulfanilo; W es S, O, o MR9; R9 es hidrogeno o alquilo C1-6, X es O, -NR6-, o-(CH2)pNR6-, R6 eshidrogeno, o alquilo C1-6; p es 1 a 4; Y es metileno, carbonilo, -SO2, o -SO-; Z es fenilo, heteroarilo, o naftilo; R7 y R8 son cada uno independientemente,hidrogeno, carboxilo, acilo C2-7, hidroxilo, hidroxialquilo C1-6, hidroxialcanoílo C1-6, alcoxicarbonilo C2-7, perfluoroalcoxicarbonilo C2-7, alquilo C1-6,perfluoroalquilo C1-6, arilo C6-12, ariloxicarbonilo C7-13, heteroariloxicarbonilo, heteroarilo, tetrazolilo, mercapto, alquilsulfanilo C1-6, nitrilo, amino,carbamoílo, aminoalquilo C1-6, alquilamino C1-6, dialquilamino C1-6 por grupo alquilo, -NHSO2CF3, carboxialdehído, halogeno, nitro, acilamino C1-6, 3-hidroxi,-ciclobut-3-eno-4-il-1,2diona, o ácido tetronico, -OCOR10, -OR10, R10 es arilo C6-12, aralquilo C7-13, heteroarilo monocíclico o bicíclico,o un heteroaralquilomonocíclico o bicíclico, alquilo C1-6, perfluroalquilo C1-6; o una sal farmacéuticamente aceptable de los mismos,que son utiles en el tratamiento de desordenesmetabolicos relacionados con la resistencia a la insulina o hiperglucemia; el uso de los mismos para la manufactura de un medicamento y una composicion que loscomprende.Naphtho [2,3-B] heteroar-4-yl derivatives of formula 1, wherein R1 and R2 are each, independently, hydrogen, nitrile, nitro, amino, C1-6 alkylamino, C1-6 dialkylamino per alkyl group, C3-8 cycloalkylamino, C1-6 alkyl perfluoralkyl C1-6, halogen, C3-8 cycloalkyl, thienyl, furyl, phenyl of mono-, di-, or trisubstituted with halogen, hydroxy, C1-6 alkyl, perfluoroalkyl C1-6, C1-6 alkoxy, or C1-6 perfluoralkoxy; R3 and R4 are each independently hydrogen, C1-6 alkyl, perfluoroalkyl C1-6, hydroxyalkyl C1-6, aminoalkyl C1-6, acyl C2-7; R5 is hydrogen, halogen, C1-6 alkyl, nitrile, C1-6 alkoxy, aryloxy, C6-12 arylalkoxy, arylsulfanyl; W is S, O, or MR9; R9 is hydrogen or C1-6 alkyl, X is O, -NR6-, or- (CH2) pNR6-, R6 is hydrogen, or C1-6 alkyl; p is 1 to 4; Y is methylene, carbonyl, -SO2, or -SO-; Z is phenyl, heteroaryl, or naphthyl; R7 and R8 are each independently, hydrogen, carboxyl, C2-7 acyl, hydroxy, C1-6 hydroxyalkyl, C1-6 hydroxyalkanoyl, C2-7 alkoxycarbonyl, C2-7 perfluoroalkoxycarbonyl, C1-6 alkyl, perfluoroalkyl C1-6, aryl C6-12, C7-13 aryloxycarbonyl, heteroaryloxycarbonyl, heteroaryl, tetrazolyl, mercapto, C1-6 alkylsulfanyl, nitrile, amino, carbamoyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 dialkylamino by alkyl group, -NHSO2CF3, carboxydehyde , halogen, nitro, C1-6 acylamino, 3-hydroxy, -cyclobut-3-eno-4-yl-1,2-dione, or tetronic acid, -OCOR10, -OR10, R10 is C6-12 aryl, C7-13 aralkyl , monocyclic or bicyclic heteroaryl, or a heteroaralkyl monocyclic or bicyclic, C1-6 alkyl, C1-6 perfluroalkyl; or a pharmaceutically acceptable salt thereof, which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia; the use of them for the manufacture of a medicine and a composition that includes them.

ARP990102225A 1998-05-12 1999-05-11 DERIVATIVES OF NAFTO [2,3-B] HETEROAR-4-ILO, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A COMPOSITION THAT INCLUDES THEM. AR019842A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7644698A 1998-05-12 1998-05-12

Publications (1)

Publication Number Publication Date
AR019842A1 true AR019842A1 (en) 2002-03-20

Family

ID=22132072

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102225A AR019842A1 (en) 1998-05-12 1999-05-11 DERIVATIVES OF NAFTO [2,3-B] HETEROAR-4-ILO, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A COMPOSITION THAT INCLUDES THEM.

Country Status (8)

Country Link
EP (1) EP1077968A1 (en)
JP (1) JP2002514639A (en)
CN (1) CN1308625A (en)
AR (1) AR019842A1 (en)
AU (1) AU3791699A (en)
CA (1) CA2330555A1 (en)
TW (1) TW446704B (en)
WO (1) WO1999058522A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2433476T3 (en) 2000-01-21 2013-12-11 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
CN100334088C (en) * 2003-05-15 2007-08-29 霍夫曼-拉罗奇有限公司 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7226915B2 (en) * 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
PL1931350T5 (en) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PT2531501E (en) 2010-02-03 2014-02-17 Takeda Pharmaceutical Apoptosis signal-regulating kinase 1 inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SG11201507288UA (en) 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
CN106749169B (en) * 2016-11-07 2020-04-21 浙江工业大学 Chiral preparation method of Ertiprotafib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9406823A (en) * 1993-06-14 1996-03-26 Pfizer Secondary amines and anti-diabetic and anti-obesity agents
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
WO1997008126A1 (en) * 1995-08-28 1997-03-06 American Home Products Corporation Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents

Also Published As

Publication number Publication date
CN1308625A (en) 2001-08-15
WO1999058522A1 (en) 1999-11-18
CA2330555A1 (en) 1999-11-18
EP1077968A1 (en) 2001-02-28
JP2002514639A (en) 2002-05-21
AU3791699A (en) 1999-11-29
TW446704B (en) 2001-07-21

Similar Documents

Publication Publication Date Title
AR019842A1 (en) DERIVATIVES OF NAFTO [2,3-B] HETEROAR-4-ILO, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A COMPOSITION THAT INCLUDES THEM.
ES2566973T9 (en) Use of SNS-595 to treat leukemia
AR032752A1 (en) UREIDO PROPIONAMIDS OR PROPIONAMIDS TRANS-HEREROAROMATIC 2,3-DI-SUBSTITUTES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL AS GLUCO ACTIVATORS
RU2006134005A (en) NEW COMPOUNDS OPERATING AS NS3 SERIN PROTEASE INHIBITORS HEPATITIS C VIRUS
AR015765A1 (en) DIHYDROPIRIMIDINES 2 HETEROCICLICALLY REPLACED, PROCESS FOR PREPARATION, DRUGS THAT CONTAIN THEM, PROCESS FOR THE PREPARATION OF THE SAME DIHYDROPIRIMIDINES FOR THE PREPARATION OF A MEDICINAL PRODUCT.
AR030053A1 (en) 1H-PIRIMIDO [4,5-D] PIRIMIDIN-2-ONAS AND SALTS, PHARMACEUTICAL COMPOSITIONS, USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR PRODUCERS
ES2077138T3 (en) DERIVATIVES OF AMINOCUMARANE, ITS PRODUCTION AND ITS USE.
KR950007853A (en) Tumor treatment method
DE69628163D1 (en) NOR-PREGNANE FOR INDUCING HYPOTHALAMIC EFFECTS
ID23808A (en) SPECIAL ARCHITECTURAL AMIDES OF AMIDA ACID AMSTICUSED CYCLE IOP
AR032592A1 (en) AMINOALCOXICARBAZOLES AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CNS DISEASES
HUP0002272A2 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
FI80877B (en) FREQUENCY REFRIGERATION FOR THERAPEUTIC USE OF REQUIREMENTS SPIRO / 4, (3 + N) / - 2-AZAALKAN-3-CARBOXYL SYRADERIVES FOR VIDEO FRAMSTAELLNING AVOID REQUIREMENTS
ATE193706T1 (en) CYCLIC AMINO ACID DERIVATIVES WITH ACE AND NEP INHIBITING ACTIVITY
EA200500882A1 (en) N-ARILSULFONIL-3-AMINOALKOXIINDOLES
ATE153666T1 (en) PHOSPHONO-ARYLETHANOLAMINE COMPOUNDS WITH ANTIHYPERGLYCEMIC AND/OR ANTIOBEMIC ACTION
AR039391A1 (en) CYCLOPENTENE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR032896A1 (en) ARILALCANO-SULFONAMIDS, PHARMACEUTICAL COMPOSITIONS, A PROCESS FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS
AR012737A1 (en) TRIPTOLIDE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES AND USES IN THE MANUFACTURE OF MEDICINES
DE69322411D1 (en) MEDICINAL COMPOSITIONS CONTAINING TANDOSPIRON OR ITS ANALOGS
FI823278A0 (en) FRAMEWORK FOR TREATMENT OF TRIAZOLOKINAZOLONER OCH DERAS SALTER
MX9405111A (en) NEW DERIVATIVES OF (1-PHENYL-1-HETEROCICLIL) METHANOL AND (1-PHENYL-1-HETEROCICLIL-METHYLAMINE).
HUT49882A (en) Process for producing new spiro square brackets open chroman-4,4'-imidazolidine square brackets closed derivatives and pharmaceutical compositions comprising these compounds as active ingredient
EA200501232A1 (en) NEW TRICYCLIC COMPOUNDS OF AZEPIN, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
AR040239A1 (en) REPLACED THIOPHENES, METHODS FOR THEIR PREPARATION, ITS USE TO PREPARE A MEDICINAL PRODUCT AND MEDICINES THAT UNDERSTAND THEM

Legal Events

Date Code Title Description
FA Abandonment or withdrawal